Bolt Biotherapeutics, Inc.(BOLT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 23 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BOLT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Bolt Biotherapeutics, Inc. (BOLT), a Healthcare sector company. BOLT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 23 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Bolt Biotherapeutics, Inc. reports quarterly revenue of $26.0K, net income of $-7.2M, free cash flow of $-8.0M. Top institutional holders of BOLT by reported 13-F value include Sofinnova Ventures, RENAISSANCE TECHNOLOGIES, Vivo Capital,, based on the most recent SEC filings. BOLT trades on the Nasdaq exchange and files with the SEC under CIK 1641281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BOLT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bolt Biotherapeutics, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$26.0K
Net Income
Q1 2026
$-7.2M
Free Cash Flow
Q1 2026
$-8.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+0.1% YoYNet Income
+47.1% YoYOperating Income
+50.6% YoYEPS (Diluted)
-979.9% YoYTotal Assets
-43.0% YoYOp. Cash Flow
+35.0% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $7.7M +0.1% | $7.7M +34.2% | $5.7M +354.7% | $1.3M +445.5% | $231.0K | — |
| Net Income | $-33.4M +47.1% | $-63.1M +28.4% | $-88.1M +10.6% | $-98.6M -62.3% | $-60.7M | — |
| Operating Income | $-36.1M +50.6% | $-73.0M +19.1% | $-90.3M +2.7% | $-92.8M -88.7% | $-49.2M | — |
| EPS (Diluted) | $-17.85 -979.9% | $-1.65 -1300.8% | $-0.12 +20.5% | $-0.15 | — | — |
| Total Assets | $56.7M -43.0% | $99.6M -56.3% | $227.8M -26.0% | $307.7M +561.2% | $46.5M | — |
| Operating Cash Flow | $-39.9M +35.0% | $-61.3M +19.9% | $-76.5M -34.1% | $-57.1M -20.6% | $-47.3M | — |
Get alerted when BOLT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Bolt Biotherapeutics, Inc. including:
Top Institutional Holders of BOLT
Sofinnova Ventures Inc
$556.4K137,721 shRENAISSANCE TECHNOLOGIES LLC
$312.0K77,225 shVivo Capital, LLC
$292.6K72,414 shPivotal bioVenture Partners Investment Advisor LLC
$172.0K42,581 shT3 Companies, LLC
$153.5K38,000 shBoard of Trustees of The Leland Stanford Junior University
$145.3K35,977 shPFIZER INC
$137.1K31,305 shLynx1 Capital Management LP
$124.4K30,800 shNan Fung Group Holdings Ltd
$118.2K29,250 shGEODE CAPITAL MANAGEMENT, LLC
$116.3K28,791 sh
| Fund | Value | Shares |
|---|---|---|
| Sofinnova Ventures Inc | $556.4K | 137,721 |
| RENAISSANCE TECHNOLOGIES LLC | $312.0K | 77,225 |
| Vivo Capital, LLC | $292.6K | 72,414 |
| Pivotal bioVenture Partners Investment Advisor LLC | $172.0K | 42,581 |
| T3 Companies, LLC | $153.5K | 38,000 |
| Board of Trustees of The Leland Stanford Junior University | $145.3K | 35,977 |
| PFIZER INC | $137.1K | 31,305 |
| Lynx1 Capital Management LP | $124.4K | 30,800 |
| Nan Fung Group Holdings Ltd | $118.2K | 29,250 |
| GEODE CAPITAL MANAGEMENT, LLC | $116.3K | 28,791 |
More Healthcare Companies
View all Healthcare →Put BOLT on your watchlist
Track score changes the day Bolt Biotherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BOLT a good stock to buy?
13F Pro's AI-powered analysis of Bolt Biotherapeutics, Inc. (BOLT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BOLT are available on the BOLT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BOLT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BOLT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bolt Biotherapeutics, Inc.'s investment landscape.